Test Declared One of the Most Pioneering Healthcare Innovations in 21st
AMSTERDAM, Netherlands, June 26 /PRNewswire/ -- Agendia BV, a world leader in gene expression analysis-based diagnostics, is pleased to announce that the company recently received a prestigious award for its groundbreaking MammaPrint(R) test from the Dutch Innovation Platform. MammaPrint, a 70-gene signature diagnostic test that predicts high or low risk of breast cancer tumor recurrence, was chosen out of more than 150 entries as the most pioneering healthcare initiative and will have the distinguished honor of being actively supported at a national level by the Dutch government.
"We are honored that the value of MammaPrint has been recognized at a governmental level for its significant impact on the management of breast cancer," said Dr. Bernhard Sixt, president and chief executive officer of Agendia. "This award provides us with the national support that will ensure that even more breast cancer patients will benefit from personalized treatment."
MammaPrint was among four healthcare innovations awarded by Dutch Health Minister Ab Klink, chairman of the Healthcare Innovation Platform, at a recent Netherlands-based Healthcare summit. The Innovation Platform is the government's initiative dedicated to advancing The Netherlands toward becoming one of the top five international countries in the areas of higher education, research and innovation by creating the conditions, establishing the connections, and developing the vision required to stimulate innovation and entrepreneurship.
"Each year, more than 13,000 women are diagnosed with breast cancer in
The Netherlands, with another 317,000 diagnosed throughout Europe and
nearly 180,000 diagnosed in the United States," said Richard Bender, MD,
FACP, Agendia's chief medical officer. "At Agendia, we are committed to
making a positive impact on the health and quality of life of
|SOURCE Agendia BV|
Copyright©2008 PR Newswire.
All rights reserved